Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scIgG) (SCIGG-176)

Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-IL17A and anti-IL17F IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can block two proinﬂammatory cytokines simultaneously. It is designed for the research of Multiple sclerosis (MS); Autoimmune diseases; Inflammatory diseases therapy.

Datasheet INQUIRY

Specifications

Targets

IL17A & IL17F

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Multiple sclerosis (MS); Autoimmune diseases; Inflammatory diseases

Targets

Target 1

IL17A

Gene ID

3605

UniProt ID

Q16552

Alternative Names

IL17A; interleukin 17A; IL17; CTLA8; IL-17; IL-17A; interleukin-17A; CTLA-8; cytotoxic T-lymphocyte-associated antigen 8; cytotoxic T-lymphocyte-associated protein 8; interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)

Target 2

IL17F

Gene ID

112744

UniProt ID

Q96PD4

Alternative Names

IL17; Interleukin 17; IL17F; Interleukin 17F; ML1; ML-1; CANDF6; IL-17F; cytokine ML-1

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scIgG) (SCIGG-176). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-IL17A x Anti-IL17F Bispecific Antibody (scIgG) (CAT#: SCIGG-176)

Specifications

Targets

Customer Reviews and Q&As